PLXNA3 and prostate cancer: In recent years, CXCL13 has been proved to be expressed at high levels in various malignant tumor tissues such as gastric cancer [25], breast cancer [26, 27], colorectal cancer [28], lung cancer [29, 30], prostate cancer [31], and lymphoma and correlated with tumor size, stage, lymph node metastasis status [25], sex hormone levels, drug treatment response [32], and tumor recurrence.